This post in the Center for Global Health Policy’s “Science Speaks” blog examines the use of stavudine, “also known as d4T, an antiretroviral treatment that was dropped in wealthy countries years ago and that the World Health Organization has recommended stop being included in treatment programs,” to treat HIV in Malawi. “[W]hile children and pregnant or breastfeeding women, as well as tuberculosis patients have access to less toxic treatments, stavudine continues to be the first treatment supplied to most Malawi patients under the terms of the country’s grant from the Global Fund to Fight AIDS, Tuberculosis and Malaria,” the blog writes, adding, “In a letter [.pdf] to Global Fund General Manager Gabriel Jaramillo and [U.S. Global AIDS Coordinator Ambassador] Eric Goosby, the Centre for Development of People (CEDEP), Health GAP (Global Access Project), and the Malawi Network of People Living with HIV/AIDS (MANET+) are asking the Global Fund to find a way to switch to first line treatment in Malawi that is acceptable to patients and World Health Organization standards” (8/15).